{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:25:37Z","timestamp":1787163937145,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Fondazione Compagnia di San Paolo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmech.2024.116334","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T03:27:25Z","timestamp":1711423645000},"page":"116334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Combining BNCT with carbonic anhydrase inhibition for mesothelioma treatment: Synthesis, in vitro, in vivo studies of ureidosulfamido carboranes"],"prefix":"10.1016","volume":"270","author":[{"given":"Alberto","family":"Lanfranco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Rakhshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyssena","family":"Renzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Zarechian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Protti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta Geninatti","family":"Crich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-2798","authenticated-orcid":false,"given":"Annamaria","family":"Deagostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116334_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ejmech.2024.116334_bib2","first-page":"7","article-title":"Multimodality treatment of malignant pleural mesothelioma","author":"Berzenji","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.ejmech.2024.116334_bib3","article-title":"Chemoresistance and metastasis in breast cancer molecular mechanisms and novel clinical strategies","volume":"11","author":"Cao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2024.116334_bib4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","article-title":"Cancer chemoresistance and its mechanisms: associated molecular factors and its regulatory role","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2024.116334_bib5","first-page":"127","article-title":"Overview of tumor cell chemoresistance mechanisms","author":"Gatti","year":"2005","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.ejmech.2024.116334_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116334_bib7","first-page":"1027","article-title":"Key indexes and the emerging tool for tumor microenvironment editing","volume":"9","author":"Dai","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116334_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.10.019","article-title":"\u201cCombo\u201d nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy","volume":"98","author":"Kemp","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106976","article-title":"Boron-containing carbonic anhydrases inhibitors","volume":"143","author":"Giovannuzzi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib10","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2174\/156802607780636690","article-title":"Carbonic Anhydrases as drug targets - an overview","volume":"7","author":"Supuran","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1517\/13543776.10.5.575","article-title":"Carbonic anhydrase inhibitors and their therapeutic potential","volume":"10","author":"Supuran","year":"2000","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116334_bib12","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.bmc.2007.04.020","article-title":"Carbonic anhydrases as targets for medicinal chemistry","volume":"15","author":"Supuran","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib13","first-page":"2877","article-title":"Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment","volume":"9","author":"Pastorek","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2024.116334_bib14","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1073\/pnas.95.13.7608","article-title":"Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers","volume":"95","author":"T\u00fcreci","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2024.116334_bib15","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1080\/13543776.2023.2245971","article-title":"Targeting carbonic anhydrases for the management of hypoxic metastatic tumors","volume":"33","author":"Supuran","year":"2023","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116334_bib16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/molecules23051045","article-title":"Cancer drug development of carbonic anhydrase inhibitors beyond the active site","volume":"23","author":"Singh","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116334_bib17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1080\/13543776.2016.1203904","article-title":"Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016)","volume":"26","author":"Lomelino","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116334_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/138955713804484749","article-title":"Recent advances in medicinal chemistry of sulfonamides. Rational design as anti-tumoral, anti-bacterial and anti-inflammatory agents","volume":"13","author":"Shah","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/14756369909030328","article-title":"Carbonic anhydrase inhibitors. Arylsulfonylureido- and arylureido-substituted aromatic and heterocyclic sulfonamides: towards selective inhibitors of carbonic anhydrase isozyme I","volume":"14","author":"Scozzafava","year":"1999","journal-title":"J. Enzym. Inhib."},{"key":"10.1016\/j.ejmech.2024.116334_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3109\/14756366.2012.746972","article-title":"Synthesis and carbonic anhydrase inhibitory properties of novel 1,4-dihydropyrimidinone substituted diarylureas","volume":"29","author":"Celik","year":"2014","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib21","doi-asserted-by":"crossref","first-page":"12029","DOI":"10.3390\/molecules200712029","article-title":"Synthesis of novel 1-(4-substituted pyridine-3-sulfonyl)-3-phenylureas with potential anticancer activity","volume":"20","author":"Szafra\u0144ski","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2024.116334_bib22","doi-asserted-by":"crossref","first-page":"6328","DOI":"10.1021\/acs.jmedchem.8b00770","article-title":"Discovery of 4-Hydroxy-3-(3-(phenylureido)benzenesulfonamides as SLC-0111 analogues for the treatment of hypoxic tumors overexpressing carbonic anhydrase IX","volume":"61","author":"Bozdag","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib23","doi-asserted-by":"crossref","first-page":"111600","DOI":"10.1016\/j.ejmech.2019.111600","article-title":"Carbonic anhydrase inhibitors based on sorafenib scaffold: design, synthesis, crystallographic investigation and effects on primary breast cancer cells","volume":"182","author":"Bozdag","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2174\/1570193X15666181029130418","article-title":"Research progress of diphenyl urea derivatives as anticancer agents and synthetic methodologies","volume":"16","author":"Wu","year":"2019","journal-title":"Mini-Reviews Org. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib25","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.3390\/ijms20236080","article-title":"Preclinical evaluation of ureidosulfamate carbonic anhydrase IX\/XII inhibitors in the treatment of cancers","volume":"20","author":"Williams","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116334_bib26","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acs.jmedchem.1c01906","article-title":"One-pot procedure for the synthesis of asymmetric substituted ureido benzene sulfonamides as effective inhibitors of carbonic anhydrase enzymes","volume":"65","author":"Vannozzi","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib27","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1080\/14756366.2022.2126463","article-title":"Design and synthesis of some new benzoylthioureido phenyl derivatives targeting carbonic anhydrase enzymes","volume":"37","author":"Najm","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib28","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1021\/jm101541x","article-title":"Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis","volume":"54","author":"Pacchiano","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib29","doi-asserted-by":"crossref","first-page":"13405","DOI":"10.3390\/ijms222413405","article-title":"Inhibitors as candidates for combination therapy of solid tumors","volume":"22","author":"Kalinin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2024.116334_bib30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/cr941195u","article-title":"The chemistry of neutron capture therapy","volume":"98","author":"Soloway","year":"1998","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02699932","article-title":"A critical assessment of boron target compounds for boron neutron capture therapy","volume":"62","author":"Hawthorne","year":"2003","journal-title":"J. Neuroonc."},{"key":"10.1016\/j.ejmech.2024.116334_bib32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10147-019-01480-4","article-title":"Boron neutron capture therapy (BNCT): a unique role in radiotherapy with a view to entering the accelerator-based BNCT era","volume":"25","author":"Suzuki","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116334_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cac2.12089","article-title":"Boron neutron capture therapy: current status and future perspectives","volume":"40","author":"Dymova","year":"2020","journal-title":"Cancer Commun."},{"key":"10.1016\/j.ejmech.2024.116334_bib34","first-page":"907","article-title":"Novel hyaluronan formulation enhances the efficacy of boron neutron capture therapy for murine mesothelioma","volume":"36","author":"Sasai","year":"2016","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2024.116334_bib35","series-title":"Carboranes","author":"Grimes","year":"2016"},{"key":"10.1016\/j.ejmech.2024.116334_bib36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0010-8545(02)00087-5","article-title":"The medicinal chemistry of carboranes","volume":"232","author":"Valliant","year":"2002","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41570-022-00400-x","article-title":"Carboranes in drug discovery, chemical biology and molecular imaging","volume":"6","author":"Marfavi","year":"2022","journal-title":"Nat. Rev. Chem"},{"key":"10.1016\/j.ejmech.2024.116334_bib38","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1021\/cr2000866","article-title":"Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds","volume":"111","author":"Issa","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib39","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1021\/cr200038x","article-title":"Carbaboranes as pharmacophores: properties, synthesis, and application strategies","volume":"111","author":"Scholz","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib40","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1021\/acs.molpharmaceut.3c00152","article-title":"A potential boron neutron capture therapy agent selectively suppresses high-grade glioma: in vitro and in vivo exploration","volume":"20","author":"Alam\u00f3n","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116334_bib41","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.xphs.2022.02.005","article-title":"Development of prodrugs for treatment of Parkinson\u2019s disease: new inorganic scaffolds for blood-brain barrier permeation","volume":"111","author":"Di Battista","year":"2022","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2024.116334_bib42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.omto.2022.01.005","article-title":"Carboranes as unique pharmacophores in antitumor medicinal chemistry","volume":"24","author":"Chen","year":"2022","journal-title":"Mol. Ther.-Oncol."},{"key":"10.1016\/j.ejmech.2024.116334_bib43","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1246\/bcsj.20200366","article-title":"Recent advances in transition metal-catalyzed selective B-H functionalization of o-carboranes","volume":"94","author":"Au","year":"2021","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"10.1016\/j.ejmech.2024.116334_bib44","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1039\/C9CS00197B","article-title":"New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies","volume":"48","author":"Stockmann","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2024.116334_bib45","first-page":"569","article-title":"Recent developments with boron as a platform for novel drug design","volume":"11","author":"Lesnikowski","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2024.116334_bib46","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.1002\/chem.202002809","article-title":"Direct introduction of an alkylsulfonamido group on C-sites of isomeric dicarba-closo-dodecaboranes: the influence of stereochemistry on inhibitory activity against the cancer-associated carbonic anhydrase IX isoenzyme","volume":"26","author":"Nekvinda","year":"2020","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejmech.2024.116334_bib47","doi-asserted-by":"crossref","first-page":"13760","DOI":"10.1002\/anie.201307583","article-title":"Carborane-based carbonic anhydrase inhibitors","volume":"52","author":"Brynda","year":"2013","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.ejmech.2024.116334_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112460","article-title":"Sulfonamido carboranes as highly selective inhibitors of cancer-specific carbonic anhydrase IX","volume":"200","author":"Dvoranova","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib49","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/cbic.202100121","article-title":"Inhibitors of CA IX enzyme based on polyhedral boron compounds","volume":"22","author":"Kugler","year":"2021","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2024.116334_bib50","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1021\/acs.jmedchem.9b00945","article-title":"Metallacarborane sulfamides: unconventional, specific, and highly selective inhibitors of carbonic anhydrase IX","volume":"62","author":"Gruner","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib51","doi-asserted-by":"crossref","unstructured":"J. Fanfrlik, J. Brynda, M. Kugler, M. Lepsik, K. Pospisilova, J. Holub, D. Hnyk, J. Nekvinda, B. Gruner, P. Rezacova, B-H\u00b7\u00b7\u00b7\u03c0 and C-H\u00b7\u00b7\u00b7\u03c0 interactions in protein-ligand complexes: carbonic anhydrase II inhibition by carborane sulfonamides, Phys. Chem. Chem. Phys., 1728-1733.","DOI":"10.1039\/D2CP04673C"},{"key":"10.1016\/j.ejmech.2024.116334_bib52","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1021\/jp410216m","article-title":"QM\/MM calculations reveal the different nature of the interaction of two carborane-based sulfamide inhibitors of human carbonic anhydrase II","volume":"117","author":"Pecina","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejmech.2024.116334_bib53","first-page":"389869","article-title":"Carborane-based carbonic anhydrase inhibitors: insight into CAII\/CAIX specificity from a high-resolution crystal structure, modeling, and quantum chemical calculations","author":"Mader","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2024.116334_bib54","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1080\/14756366.2020.1816996","article-title":"The structural basis for the selectivity of sulfonamido dicarbaboranes toward cancer-associated carbonic anhydrase IX","volume":"35","author":"Kugler","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib55","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41598-023-27625-0","article-title":"A novel pH sensitive theranostic PLGA nanoparticle for boron neutron capture therapy in mesothelioma treatment","volume":"13","author":"Sforzi","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116334_bib56","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1039\/D2OB00764A","article-title":"Biotinylation of a MRI\/Gd BNCT theranostic agent to access a novel tumour-targeted delivery system","volume":"20","author":"Lanfranco","year":"2022","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76370-1","article-title":"In vitro and in vivo BNCT investigations using a carborane containing sulfonamide targeting CAIX epitopes on malignant pleural mesothelioma and breast cancer cells","volume":"10","author":"Alberti","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2024.116334_bib58","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.bmcl.2008.03.012","article-title":"Investigations of the esterase, phosphatase, and sulfatase activities of the cytosolic mammalian carbonic anhydrase isoforms I, II, and XIII with 4-nitrophenyl esters as substrates","volume":"18","author":"Innocenti","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116334_bib59","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1021\/bi0475471","article-title":"Directed evolution of the promiscuous esterase activity of carbonic anhydrase II","volume":"44","author":"Gould","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2024.116334_bib60","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejmech.2017.12.049","article-title":"Design, synthesis and biological evaluation of novel pyridine-thiazolidinone derivatives as anticancer agents: targeting human carbonic anhydrase IX","volume":"144","author":"Ansari","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib61","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3109\/14756366.2014.1001754","article-title":"Esterase activity of carbonic anhydrases serves as surrogate for selecting antibodies blocking hydratase activity","volume":"30","author":"Uda","year":"2015","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1072337","article-title":"Biochemical and in silico inhibition of bovine and human carbonic anhydrase-II by 1H-1,2,3-triazole analogs","volume":"10","author":"Khan","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib63","doi-asserted-by":"crossref","first-page":"103324","DOI":"10.1016\/j.bioorg.2019.103324","article-title":"Design, synthesis and preliminary in-vitro studies of novel boronated monocarbonyl analogues of Curcumin (BMAC) for antitumor and \u03b2-amiloyd disaggregation activity","volume":"93","author":"Azzi","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib64","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4161\/cc.8.3.7608","article-title":"Does the cell number 109 still really fit one gram of tumor tissue?","volume":"8","author":"Del Monte","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2024.116334_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2019.12.021","article-title":"Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity","volume":"319","author":"Kim","year":"2020","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2024.116334_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110425","article-title":"Micelles via self-assembly of amphiphilic beta-cyclodextrin block copolymers as drug carrier for cancer therapy","volume":"183","author":"Li","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejmech.2024.116334_bib67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/mp049966y","article-title":"Antitumor activity of \u03b2-cyclodextrin Polymer\u2212Camptothecin conjugates","volume":"1","author":"Cheng","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2024.116334_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jorganchem.2024.123052","article-title":"Synthesis of closo- and nido-carborane derivatives of the KRGD peptide","volume":"1008","author":"Gruzdev","year":"2024","journal-title":"J. Organomet. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1055\/s-0031-1289910","article-title":"Synthesis of complex glycosylated carboranes for BNCT","volume":"2012","author":"Campo","year":"2012","journal-title":"Synlett"},{"key":"10.1016\/j.ejmech.2024.116334_bib70","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/ic00036a043","article-title":"Development of carborane synthons: synthesis and chemistry of (aminoalkyl)carboranes","volume":"31","author":"Wilson","year":"1992","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.ejmech.2024.116334_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nimb.2017.10.023","article-title":"Neutron flux and gamma dose measurement in the BNCT irradiation facility at the TRIGA reactor of the University of Pavia","volume":"414","author":"Bortolussi","year":"2018","journal-title":"Nucl. Instruments Methods Phys. Res. Sect. B Beam Interact. Mater. Atoms"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424002149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T07:10:07Z","timestamp":1738393807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":71,"alternative-id":["S0223523424002149"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116334","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining BNCT with carbonic anhydrase inhibition for mesothelioma treatment: Synthesis, in vitro, in vivo studies of ureidosulfamido carboranes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116334"}}